Search results for "Lipoproteins."

showing 10 items of 492 documents

Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health.

2003

Oxidation of low-density lipoprotein (LDL) and hyperhomocysteinemia are believed to play a role in therogenesis. Whether n-3 polyunsaturated fatty acids increase LDL susceptibility to oxidation or influence homocysteine (Hcy) metabolism has long been a subject of controversy. In this study, we evaluated the effect of 8 weeks of dietary supplementation with 6 g/day of fish oil (FO; 3 g of n-3 fatty acids) on plasma lipoproteins, in vitro LDL peroxidation, antioxidant status, and plasma Hcy concentrations in 16 normolipidemic subjects. FO rapidly and significantly (P < .01) decreased plasma total and very low density lipoprotein triglyceride concentrations and had no effect on LDL or high-den…

AdultMalemedicine.medical_specialtyalpha-TocopherolNitric OxideThiobarbituric Acid Reactive SubstancesPathology and Forensic Medicinechemistry.chemical_compoundHigh-density lipoproteinFish OilsDietary Fats UnsaturatedInternal medicineFatty Acids Omega-3medicineHumansHomocysteineNitritesTriglycerideschemistry.chemical_classificationNitratesTriglycerideCholesterolCholesterol HDLGeneral MedicineCholesterol LDLMiddle Agedbeta CaroteneEicosapentaenoic acidGlutathioneLipoproteins LDLEndocrinologychemistryBiochemistryDocosahexaenoic acidLow-density lipoproteinFemaleLipid PeroxidationCopperPolyunsaturated fatty acidLipoproteinThe Journal of laboratory and clinical medicine
researchProduct

Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I

1998

Plasmas of patients with Tangier disease (TD) lack lipid-rich α-HDL which, in normal plasma, constitutes the majority of high density lipoprotein (HDL). Residual amounts of apolipoprotein (apo)A-I in TD plasma occur as lipid-poor or even lipid-free preβ-HDL. By contrast to normal plasma, TD plasma does not convert preβ-HDL into α-HDL. Moreover, fibroblasts of TD patients were found to be defective in secreting cholesterol or phospholipids in the presence of lipid-free apoA-I. We have therefore hypothesized that both defective conversion of preβ-HDL into α-HDL and defective lipid efflux from TD cells onto lipid-free apoA-I result from a disturbance in phospholipid transfer occurring in both …

AdultMaletransferring phospholipidsPhospholipidTangier diseasePhosphatidic AcidsQD415-436PhosphatidylinositolsBiochemistrychemistry.chemical_compoundEndocrinologyTangier diseasePhosphatidylcholinePhospholipid transfer proteinExtracellularmedicineHumansCells CulturedPhosphatidylethanolamineApolipoprotein A-ICholesterolPhosphatidylethanolaminesReverse cholesterol transportnutritional and metabolic diseasesBiological TransportCell BiologyFibroblastsmedicine.diseaseMolecular biologyfamilial HDL deficiencyreverse cholesterol transportLipoproteins LDLphospholipid transfer proteinsprebeta-HDLTangier disease; transferring phospholipidschemistryPhosphatidylcholinesFemalelipids (amino acids peptides and proteins)cholesterol efflux
researchProduct

Effect of continuous oestradiol-medroxyprogesterone administration on plasma lipids and lipoproteins

1991

Plasma lipids and lipoproteins were measured in 21 post-menopausal women after 4 and 8 months of continuous treatment with an orally administered combination of oestradiol and medroxyprogesterone acetate. The mean concentrations of cholesterol and low-density-lipoprotein (LDL) cholesterol were reduced by 12% (P less than 0.001) and 11% (P less than 0.01), respectively, after 4 months of treatment and by 9% (P less than 0.05) and 12% (P less than 0.05) after 8 months. The mean level of high-density-lipoprotein (HDL) cholesterol showed an initial fall of 5% (P less than 0.05) after 4 months and then increased by 13% (P less than 0.05) after 8 months of treatment. The plasma triglycerides leve…

AdultMedroxyprogesteronemedicine.medical_specialtymedicine.drug_classLipoproteinsMedroxyprogesteronemedicine.medical_treatmentGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundInternal medicinePlasma lipidsHumansMedicineMedroxyprogesterone acetateClinical significanceProspective StudiesEstradiolProgestogenbusiness.industryCholesterolEstrogen Replacement TherapyObstetrics and GynecologyMiddle AgedLipidsEndocrinologychemistryEstrogenDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Menopausebusinessmedicine.drugLipoproteinMaturitas
researchProduct

Validating a Rapid Method for Detecting Common Polymorphisms in the APOA5 Gene by Melting Curve Analysis Using LightTyper

2005

The recently identified apolipoprotein A-V gene (APOA5) has been shown to play an important role in hypertriglyceridemia (1). Genetic variation in APOA5 has been consistently associated with plasma triglyceride concentrations in several studies (2)(3)(4). Moreover, some studies have demonstrated additional associations with lipoprotein subclasses, remnant-like particles, and cardiovascular disease risk (4)(5)(6). Several single-nucleotide polymorphisms (SNPs) in the human APOA5 gene have been detected with differing frequencies depending on the population analyzed (7)(8), and Klos et al.(7) have also suggested context-dependent associations in different populations. Overall, 5 common SNPs, …

AdultNonsynonymous substitutionAdolescentGenotypeClinical BiochemistryPopulationSingle-nucleotide polymorphismBiologyPolymerase Chain ReactionMelting curve analysisHumanseducationGenotypingApolipoproteins AAgedGeneticseducation.field_of_studyPolymorphism GeneticBiochemistry (medical)HaplotypeMiddle AgedSNP genotypingApolipoproteinsApolipoprotein A-VRestriction fragment length polymorphismPolymorphism Restriction Fragment LengthClinical Chemistry
researchProduct

Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype

2017

BACKGROUND: Dyslipidemia is common in women with polycystic ovary syndrome (PCOS) but its prevalence in different PCOS phenotypes is still largely unknown. METHODS: We measured plasma lipids and lipoproteins in 35 anovulatory PCOS (age: 25 ± 6 years, BMI: 28 ± 6 kg/m2), 15 ovulatory PCOS (age: 30 ± 6 years, BMI: 25 ± 3 kg/m2) and 27 healthy women (controls) age- and BMI-matched with ovulatory PCOS. PCOS was diagnosed by the presence of clinical or biologic hyperandrogenism associated with chronic anovulation and/or polycystic ovaries at ultrasound. In women with normal menses chronic anovulation was indicated by low serum progesterone levels (&lt;9.54 nmol/l) during midluteal phase (days 21…

AdultOvulationmedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseases10265 Clinic for Endocrinology and Diabetology610 Medicine & healthBiologyAnovulationchemistry.chemical_compoundInsulin resistancepolycystic ovary syndrome lipids lipoproteins cardiovascular riskRisk FactorsInternal medicinemedicineHumansTriglyceridesTestosteroneDyslipidemiasTriglycerideRehabilitationHyperandrogenismObstetrics and Gynecologynutritional and metabolic diseases2729 Obstetrics and GynecologyCholesterol LDL2743 Reproductive MedicineAtherosclerosismedicine.diseasePolycystic ovarySettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsCholesterolEndocrinologyReproductive Medicinechemistry10036 Medical ClinicFemalelipids (amino acids peptides and proteins)DyslipidemiaPolycystic Ovary SyndromeLipoprotein
researchProduct

Interleukin-18 levels are associated with low-density lipoproteins size

2009

INTRODUCTION: Both low-density lipoproteins (LDL) size and serum interleukin (IL)-18 levels have been shown to be predictors of cardiovascular morbidity and mortality. However, it is still unknown whether IL-18 levels are independently associated with LDL size. METHODS: In this cross-sectional study including 53 premenopausal women (18-45 years), LDL size (by gradient gel electrophoresis), serum IL-18, high-sensitivity C-reactive protein (hs-CRP), serum lipids, insulin sensitivity (S(I), by frequently sampled intravenous glucose tolerance test) were measured. RESULTS: LDL size correlated with IL-18 (r = -0.38, P = 0.006), hs-CRP (r = -0.40, P = 0.003), S(I) (r = 0.36, P = 0.011), serum trig…

Adultmedicine.medical_specialty1303 BiochemistryAdolescentClinical Biochemistry10265 Clinic for Endocrinology and DiabetologyBlood lipidsInflammation610 Medicine & health1308 Clinical BiochemistryBiochemistryYoung AdultInternal medicinemedicineHumansRisk factorProspective cohort studyBeta (finance)TriglyceridesSubclinical infectionElectrophoresis Agar Gelbusiness.industryInterleukin-18InterleukinGeneral MedicineMiddle AgedLipoproteins LDLEndocrinologyC-Reactive ProteinCholesterolCross-Sectional StudiesCardiovascular Diseases10076 Center for Integrative Human Physiology570 Life sciences; biologylipids (amino acids peptides and proteins)Interleukin 18Femalemedicine.symptomInsulin Resistancebusinessaterosclerosi
researchProduct

Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.

2006

Abstract Context: An altered lipid profile is common in polycystic ovary syndrome (PCOS) and is usually characterized by increased triglycerides and low high-density lipoprotein (HDL)-cholesterol levels. In the general population, these alterations are often associated with the increase of small low-density lipoproteins (LDLs) in the so-called “atherogenic lipoprotein phenotype” (ALP) that determines a further increase of cardiovascular risk. In this study, we evaluated the presence of ALP in the plasma of women with PCOS. Setting: Measurements and analysis of LDL size were performed at the Clinic of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital, Zurich. PCOS patients…

Adultmedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryPopulationClinical nutritionBiologyBiochemistryAnovulationEndocrinologyDiabetes mellitusInternal medicinemedicineHumansInsulinParticle SizeeducationTriglyceridesAtherogenic lipoprotein low-density lipoproteins polycystic ovary syndromeeducation.field_of_studymedicine.diagnostic_testBiochemistry (medical)HyperandrogenismCholesterol HDLnutritional and metabolic diseasesmedicine.diseasePolycystic ovaryLipoproteins LDLEndocrinologyPhenotypelipids (amino acids peptides and proteins)FemaleLipid profileLipoproteinPolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct

Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells.

2006

Objective: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthase, is a novel cardiovascular risk factor produced by endothelial cells. ADMA levels are mainly regulated by the activity of dimethylarginine dimethylaminohydrolases (DDAH). Endothelial release of ADMA is increased in the presence of oxidized LDL cholesterol (oxLDL), whereas estrogens stimulate NO production by endothelial cells by increasing both expression and activity of NO synthase and by reducing ADMA levels. Thus, the aim of the present study was to evaluate the estradiol effects on the DDAH/ADMA/NO pathway in cultured human umbilical vein endothelial cells (HUVEC) exposed to LDL. Methods…

Adultmedicine.medical_specialtyEndotheliumPhysiologymedicine.drug_classImmunoblottingGene ExpressionBiologyArginineNitric OxideUmbilical veinNitric oxideAmidohydrolaseschemistry.chemical_compoundPhysiology (medical)Internal medicinemedicineElectrochemistryHumansRNA MessengerCells CulturedChromatography High Pressure LiquidAnalysis of VarianceEstradiolReverse Transcriptase Polymerase Chain ReactionEndothelial CellsEndothelial stem cellNitric oxide synthaseLipoproteins LDLmedicine.anatomical_structureEndocrinologychemistryCell cultureEstrogenbiology.proteinEndothelium VascularNitric Oxide SynthaseCardiology and Cardiovascular MedicineAsymmetric dimethylarginineCardiovascular research
researchProduct

Extracorporeal circuit heparinization in selective low density lipoprotein apheresis: changes in patient hemostasis and low molecular weight heparin …

1993

Treatment by low density lipoprotein (LDL) apheresis using dextran sulfate columns (DSC) leads to hemostasis alterations with prolonged activated partial thromboplastin time (APTT) of more than 120 seconds. In order to explain this hypocoagulability, we studied hemostasis parameters both in patients and in the extracorporeal circulation (ECC). Hemostasis changes are first related to unfractionated heparin (UFH)—needed to avoid circuit coagulation—which leads to high residual heparinemia in the patient (more than 3 times the recommended level for therapeutic use). Second, the hypocoagulability is induced by a coagulation factor decrease (primarily factors V, VIH, and X) mainly due to an adso…

Adultmedicine.medical_specialtyExtracorporeal Circulationmedicine.drug_classLow molecular weight heparinHyperlipoproteinemia Type IIInternal medicinemedicineHumansHemostasismedicine.diagnostic_testbusiness.industryExtracorporeal circulationAnticoagulantDextran SulfateNadroparinHematologyGeneral MedicineHeparinMiddle AgedBlood Coagulation FactorsSurgeryLipoproteins LDLApheresisLDL apheresisHemostasisCardiologyBlood Component RemovalbusinessPartial thromboplastin timemedicine.drugJournal of clinical apheresis
researchProduct

Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.

2009

OBJECTIVE: Dyslipidaemia is very common in patients with polycystic ovary syndrome (PCOS) but, beyond plasma lipids, atherogenic lipoprotein (Lp) and apolipoprotein (apo) alterations are still ill defined. DESIGN: We measured concentrations of apoB, Lp(a) and small, dense low-density lipoprotein (LDL) in 42 patients with PCOS [age: 28 +/- 7 years, body mass index (BMI): 27 +/- 5 kg/m(2)] vs. 37 age- and BMI-matched healthy controls. METHODS: Elevated Lp(a) levels considered were those > 30 mg/dl while elevated apoB concentrations were those > 100 g/l. RESULTS: Polycystic ovary syndrome showed increased triglycerides levels (p = 0.0011) and lower high-density lipoprotein (HDL)-cholesterol co…

Adultmedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein B10265 Clinic for Endocrinology and Diabetology610 Medicine & health2700 General MedicineSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compoundYoung AdultRisk FactorsInternal medicinemedicinedyslipidemia lipoproteins polycystic ovary syndromeHumansProspective cohort studyApolipoproteins BDyslipidemiasbiologyCholesterolbusiness.industryVascular diseaseCase-control studynutritional and metabolic diseasesGeneral MedicineCholesterol LDLmedicine.diseasePolycystic ovaryEndocrinologychemistry10036 Medical ClinicCardiovascular DiseasesCase-Control Studiesbiology.proteinlipids (amino acids peptides and proteins)FemalebusinessBody mass indexLipoproteinLipoprotein(a)Polycystic Ovary SyndromeInternational journal of clinical practice
researchProduct